{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:32:05Z","timestamp":1772447525932,"version":"3.50.1"},"reference-count":68,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CGT"],"published-print":{"date-parts":[[2020,4,25]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Epilepsy is a syndrome specified by frequent seizures and is one of the most prevalent neurological\nconditions, and that one-third of people of epilepsy are resistant to available drugs. Surgery\nis supposed to be the main treatment for the remedy of multiple drug-resistant epilepsy, but it is a\ndrastic procedure. Advancement in genomic technologies indicates that gene therapy can make such\nsurgery unnecessary. The considerable number of new studies show the significance of mutation in\nmammalian target of rapamycin pathway, NMDA receptors, GABA receptors, potassium channels and\nG-protein coupled receptors. Illustration of the meticulous drug in epilepsy targeting new expression\nof mutations in SCN8A, GRIN2A, GRIN2D and KCNT1 are conferred. Various methods are utilized\nto express a gene in a precise area of the brain; Transplantation of cells in an ex vivo approach (fetal\ncells, fibroblasts, immortalized cells), nonviral vector delivery and viral vector delivery like retrovirus,\nherpes simplex virus adenovirus and adeno-related virus. Gene therapy has thus been explored to generate\nanti-epileptogenic, anti-seizure and disease-modifying effects. Specific targeting of the epileptogenic\nregion is facilitated by gene therapy, hence sparing the adjacent healthy tissue and decreasing\nthe adverse effects that frequently go hand in hand with antiepileptic medication.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1566523220666200131142423","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T14:09:17Z","timestamp":1580479757000},"page":"367-375","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Gene Therapy Repairs for the Epileptic Brain: Potential for Treatment and Future Directions"],"prefix":"10.2174","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6882-5581","authenticated-orcid":true,"given":"Md. A.","family":"Ahmad","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Faculty of Pharmacy, Integral University, Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2577-7505","authenticated-orcid":true,"given":"Faheem H.","family":"Pottoo","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, College of Clinical Pharmacy, Imam Abdul Rahman Bin Faisal University, P.O. Box 1982, Dammam, 31441, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5117-9413","authenticated-orcid":true,"given":"Md.","family":"Akbar","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmaceutical, Education and Research, Jamia Hamdard, New Delhi- 110062, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"111","volume":"15","author":"Nagabhushan KS","year":"2013","unstructured":"Nagabhushan KS; Khan N.N.; Gray S.J.; Recent gene therapy advancements for neurological diseases. Discov Med 2013,15(81),111-119","journal-title":"Discov Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s12035-018-1121-x","volume":"56","author":"Pottoo F.H.","year":"2019","unstructured":"Pottoo F.H.; Tabassum N.; Javed M.N.; Nigar S.; Rasheed R.; Khan A.; Barkat M.A.; Alam M.S.; Maqbool A.; Ansari M.A.; Barreto G.E.; Ashraf G.M.; The synergistic effect of raloxifene, fluoxetine, and bromocriptine protects against pilocarpine-induced status epilepticus and temporal lobe epilepsy. Mol Neurobiol 2019,56(2),1233-1247","journal-title":"Mol Neurobiol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9734\/JAMPS\/2016\/24441","volume":"10","author":"Nigar S.","year":"2016","unstructured":"Nigar S.; Pottoo F.H.; Tabassum N.; Verma S.K.; Javed M.N.; Molecular insights into the role of inflammation and oxidative stress in epilepsy. J Adv Med PharmSci 2016,10,1-9","journal-title":"J Adv Med PharmSci"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.pneurobio.2007.10.010","volume":"84","author":"Acharya M.M.","year":"2008","unstructured":"Acharya M.M.; Hattiangady B.; Shetty A.K.; Progress in neuroprotective strategies for preventing epilepsy. Prog Neurobiol 2008,84(4),363-404","journal-title":"Prog Neurobiol"},{"key":"ref=5","first-page":"55","volume":"43","author":"Chepurnov S.A.","year":"2012","unstructured":"Chepurnov S.A.; Sule\u012dmanova E.M.; Guliaev M.V.; Abbasova K.R.; Pirogov IuA.; Chepurnova N.E.; [Neuroprotection in epilepsy]. Usp Fiziol Nauk 2012,43(2),55-71","journal-title":"Usp Fiziol Nauk"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ejps.2014.09.002","volume":"65","author":"Pottoo F.H.","year":"2014","unstructured":"Pottoo F.H.; Bhowmik M.; Vohora D.; Raloxifene protects against seizures and neurodegeneration in a mouse model mimicking epilepsy in postmenopausal woman. Eur J Pharm Sci 2014,65,167-173","journal-title":"Eur J Pharm Sci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/j.1528-1167.2011.03391.x","volume":"53","author":"Galanopoulou A.S.","year":"2012","unstructured":"Galanopoulou A.S.; Buckmaster P.S.; Staley K.J.; Mosh\u00e9 S.L.; Perucca E.; Engel J.; L\u00f6scher W.; Noebels J.L.; Pitk\u00e4nen A.; Stables J.; White H.S.; O\u2019Brien T.J.; Simonato M.; Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia 2012,53(3),571-582","journal-title":"Epilepsia"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrneurol.2013.56","volume":"9","author":"Simonato M.","year":"2013","unstructured":"Simonato M.; Bennett J.; Boulis N.M.; Castro M.G.; Fink D.J.; Goins W.F.; Gray S.J.; Lowenstein P.R.; Vandenberghe L.H.; Wilson T.J.; Wolfe J.H.; Glorioso J.C.; Progress in gene therapy for neurological disorders. Nat Rev Neurol 2013,9(5),277-291","journal-title":"Nat Rev Neurol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.tips.2006.10.002","volume":"27","author":"Simonato M.","year":"2006","unstructured":"Simonato M.; Tongiorgi E.; Kokaia M.; Angels and demons: neurotrophic factors and epilepsy. Trends Pharmacol Sci 2006,27(12),631-638","journal-title":"Trends Pharmacol Sci"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1006\/mthe.2002.0701","volume":"6","author":"Haberman R.","year":"2002","unstructured":"Haberman R.; Criswell H.; Snowdy S.; Ming Z.; Breese G.; Samulski R.; McCown T.; Therapeutic liabilities of in vivo viral vector tropism: adeno-associated virus vectors, NMDAR1 antisense, and focal seizure sensitivity. Mol Ther 2002,6(4),495-500","journal-title":"Mol Ther"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1093\/brain\/awq219","volume":"133","author":"Woldbye D.P.","year":"2010","unstructured":"Woldbye D.P.; Angehagen M.; G\u00f8tzsche C.R.; Elbr\u00f8nd-Bek H.; S\u00f8rensen A.T.; Christiansen S.H.; Olesen M.V.; Nikitidou L.; Hansen T.V.; Kanter-Schlifke I.; Kokaia M.; Adeno-associated viral vector-induced overexpression of neuropeptide Y Y2 receptors in the hippocampus suppresses seizures. Brain 2010,133(9),2778-2788","journal-title":"Brain"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.tins.2006.05.009","volume":"29","author":"Berkovic S.F.","year":"2006","unstructured":"Berkovic S.F.; Mulley J.C.; Scheffer I.E.; Petrou S.; Human epilepsies: interaction of genetic and acquired factors. Trends Neurosci 2006,29(7),391-397","journal-title":"Trends Neurosci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1528-1167.2008.01743.x","volume":"50","author":"Riban V.","year":"2009","unstructured":"Riban V.; Fitzsimons H.L.; During M.J.; Gene therapy in epilepsy. Epilepsia 2009,50(1),24-32","journal-title":"Epilepsia"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1535-7597.2004.43001.x","volume":"4","author":"Vezzani A.","year":"2004","unstructured":"Vezzani A.; Gene therapy in epilepsy. Epilepsy Curr 2004,4(3),87-90","journal-title":"Epilepsy Curr"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1212\/WNL.0000000000000790","volume":"83","author":"Vadlamudi L.","year":"2014","unstructured":"Vadlamudi L.; Milne R.L.; Lawrence K.; Heron S.E.; Eckhaus J.; Keay D.; Connellan M.; Torn-Broers Y.; Howell R.A.; Mulley J.C.; Scheffer I.E.; Dibbens L.M.; Hopper J.L.; Berkovic S.F.; Genetics of epilepsy: The testimony of twins in the molecular era. Neurology 2014,83(12),1042-1048","journal-title":"Neurology"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/WCO.0000000000000433","volume":"30","author":"Symonds J.D.","year":"2017","unstructured":"Symonds J.D.; Zuberi S.M.; Johnson M.R.; Advances in epilepsy gene discovery and implications for epilepsy diagnosis and treatment. Curr Opin Neurol 2017,30(2),193-199","journal-title":"Curr Opin Neurol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.ymthe.2005.12.013","volume":"13","author":"Laing J.M.","year":"2006","unstructured":"Laing J.M.; Gober M.D.; Golembewski E.K.; Thompson S.M.; Gyure K.A.; Yarowsky P.J.; Aurelian L.; Intranasal administration of the growth-compromised HSV-2 vector DeltaRR prevents kainate-induced seizures and neuronal loss in rats and mice. Mol Ther 2006,13(5),870-881","journal-title":"Mol Ther"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1089\/hum.2005.16.408","volume":"16","author":"Muzyczka N.","year":"2005","unstructured":"Muzyczka N.; Warrington K.H.; Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism. Hum Gene Ther 2005,16(4),408-416","journal-title":"Hum Gene Ther"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S1046-2023(02)00222-0","volume":"28","author":"Ruitenberg M.J.","year":"2002","unstructured":"Ruitenberg M.J.; Eggers R.; Boer G.J.; Verhaagen J.; Adeno-associated viral vectors as agents for gene delivery: application in disorders and trauma of the central nervous system. Methods 2002,28(2),182-194","journal-title":"Methods"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/glia.1101","volume":"36","author":"Hickey W.F.","year":"2001","unstructured":"Hickey W.F.; Basic principles of immunological surveillance of the normal central nervous system. Glia 2001,36(2),118-124","journal-title":"Glia"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1602\/neurorx.1.4.472","volume":"1","author":"Barker R.A.","year":"2004","unstructured":"Barker R.A.; Widner H.; Immune problems in central nervous system cell therapy. NeuroRx 2004,1(4),472-481","journal-title":"NeuroRx"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2174\/0929867043456160","volume":"11","author":"Ewert K.","year":"2004","unstructured":"Ewert K.; Slack N.L.; Ahmad A.; Evans H.M.; Lin A.J.; Samuel C.E.; Safinya C.R.; Cationic lipid-DNA complexes for gene therapy: understanding the relationship between complex structure and gene delivery pathways at the molecular level. Curr Med Chem 2004,11(2),133-149","journal-title":"Curr Med Chem"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/978-1-62703-462-3_21","volume":"1025","author":"Pezzoli D.","year":"2013","unstructured":"Pezzoli D.; Kajaste-Rudnitski A.; Chiesa R.; Candiani G.; Lipid-based nanoparticles as nonviral gene delivery vectors. Methods Mol Biol 2013,1025,269-279","journal-title":"Methods Mol Biol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S0959-437X(00)00237-9","volume":"11","author":"Rathjen J.","year":"2001","unstructured":"Rathjen J.; Rathjen P.D.; Mouse ES cells: experimental exploitation of pluripotent differentiation potential. Curr Opin Genet Dev 2001,11(5),587-594","journal-title":"Curr Opin Genet Dev"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1089\/neu.2006.0141","volume":"24","author":"Riess P.","year":"2007","unstructured":"Riess P.; Molcanyi M.; Bentz K.; Maegele M.; Simanski C.; Carlitscheck C.; Schneider A.; Hescheler J.; Bouillon B.; Sch\u00e4fer U.; Neugebauer E.; Embryonic stem cell transplantation after experimental traumatic brain injury dramatically improves neurological outcome, but may cause tumors. J Neurotrauma 2007,24(1),216-225","journal-title":"J Neurotrauma"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nm0397-350","volume":"3","author":"Deacon T.","year":"1997","unstructured":"Deacon T.; Schumacher J.; Dinsmore J.; Thomas C.; Palmer P.; Kott S.; Edge A.; Penney D.; Kassissieh S.; Dempsey P.; Isacson O.; Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson\u2019s disease. Nat Med 1997,3(3),350-353","journal-title":"Nat Med"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/096368970000900212","volume":"9","author":"Fink J.S.","year":"2000","unstructured":"Fink J.S.; Schumacher J.M.; Ellias S.L.; Palmer E.P.; Saint-Hilaire M.; Shannon K.; Penn R.; Starr P.; VanHorne C.; Kott H.S.; Dempsey P.K.; Fischman A.J.; Raineri R.; Manhart C.; Dinsmore J.; Isacson O.; Porcine xenografts in Parkinson\u2019s disease and Huntington\u2019s disease patients: preliminary results. Cell Transplant 2000,9(2),273-278","journal-title":"Cell Transplant"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/nm0997-964","volume":"3","author":"Isacson O.","year":"1997","unstructured":"Isacson O.; Breakefield X.O.; Benefits and risks of hosting animal cells in the human brain. Nat Med 1997,3(9),964-969","journal-title":"Nat Med"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/sj.mt.6300018","volume":"15","author":"Berges B.K.","year":"2007","unstructured":"Berges B.K.; Wolfe J.H.; Fraser N.W.; Transduction of brain by herpes simplex virus vectors. Mol Ther 2007,15(1),20-29","journal-title":"Mol Ther"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S0306-4522(97)00513-7","volume":"83","author":"McMenamin M.M.","year":"1998","unstructured":"McMenamin M.M.; Byrnes A.P.; Charlton H.M.; Coffin R.S.; Latchman D.S.; Wood M.J.A.; A gamma34.5 mutant of herpes simplex 1 causes severe inflammation in the brain. Neuroscience 1998,83(4),1225-1237","journal-title":"Neuroscience"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1471-2202-9-37","volume":"9","author":"Cao H.","year":"2008","unstructured":"Cao H.; Zhang G.R.; Wang X.; Kong L.; Geller A.I.; Enhanced nigrostriatal neuron-specific, long-term expression by using neural-specific promoters in combination with targeted gene transfer by modified helper virus-free HSV-1 vector particles. BMC Neurosci 2008,9,37","journal-title":"BMC Neurosci"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.ymthe.2005.11.012","volume":"13","author":"Jakobsson J.","year":"2006","unstructured":"Jakobsson J.; Lundberg C.; Lentiviral vectors for use in the central nervous system. Mol Ther 2006,13(3),484-493","journal-title":"Mol Ther"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/978-1-59745-030-0_20","volume":"366","author":"Zhao J.","year":"2007","unstructured":"Zhao J.; Lever A.M.; Lentivirus-mediated gene expression. Methods Mol Biol 2007,366,343-355","journal-title":"Methods Mol Biol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/(SICI)1097-4547(19980115)51:2<196::\n AID-JNR8>3.0.CO;2-8","volume":"51","author":"L\u00f6scher W","year":"1998","unstructured":"L\u00f6scher W; Ebert U; Lehmann H; Rosenthal C; Nikkhah G; Seizure\n suppression in kindling epilepsy by grafts of fetal GABAergic neurons\n in rat substantia nigra. J Neurosci Res 1998,51(2),196-209","journal-title":"J Neurosci Res"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1006\/exnr.1999.7305","volume":"161","author":"Thompson K.","year":"2000","unstructured":"Thompson K.; Anantharam V.; Behrstock S.; Bongarzone E.; Campagnoni A.; Tobin A.J.; Conditionally immortalized cell lines, engineered to produce and release GABA, modulate the development of behavioral seizures. Exp Neurol 2000,161(2),481-489","journal-title":"Exp Neurol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1159\/000085102","volume":"48","author":"Liu W.","year":"2005","unstructured":"Liu W.; He X.; Cao Z.; Sheng J.; Liu H.; Li Z.; Li W.; Efficient therapeutic gene expression in cultured rat hippocampal neurons mediated by human foamy virus vectors: a potential for the treatment of neurological diseases. Intervirology 2005,48(5),329-335","journal-title":"Intervirology"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1212\/WNL.0000000000003087","volume":"87","author":"Johannesen K.","year":"2016","unstructured":"Johannesen K.; Marini C.; Pfeffer S.; M\u00f8ller R.S.; Dorn T.; Niturad C.E.; Gardella E.; Weber Y.; S\u00f8nderg\u00e5rd M.; Hjalgrim H.; Nikanorova M.; Becker F.; Larsen L.H.; Dahl H.A.; Maier O.; Mei D.; Biskup S.; Klein K.M.; Reif P.S.; Rosenow F.; Elias A.F.; Hudson C.; Helbig K.L.; Schubert-Bast S.; Scordo M.R.; Craiu D.; Dj\u00e9mi\u00e9 T.; Hoffman-Zacharska D.; Caglayan H.; Helbig I.; Serratosa J.; Striano P.; De Jonghe P.; Weckhuysen S.; Suls A.; Muru K.; Talvik I.; Talvik T.; Muhle H.; Borggraefe I.; Rost I.; Guerrini R.; Lerche H.; Lemke J.R.; Rubboli G.; Maljevic S.; Phenotypic spectrum of GABRA1: From generalized epilepsies to severe epileptic encephalopathies. Neurology 2016,87(11),1140-1151","journal-title":"Neurology"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ajhg.2016.06.003","volume":"99","author":"Consortium E.","year":"2016","unstructured":"Consortium E.; De Novo Mutations in SLC1A2 and CACNA1A are important causes of epileptic encephalopathies. Am J Hum Genet 2016,99(2),287-298","journal-title":"Am J Hum Genet"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/ana.24631","volume":"79","author":"Janve V.S.","year":"2016","unstructured":"Janve V.S.; Hernandez C.C.; Verdier K.M.; Hu N.; Macdonald R.L.; Epileptic encephalopathy de novo GABRB mutations impair GABAA receptor function. Ann Neurol 2016,79,806-825","journal-title":"Ann Neurol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/ng.677","volume":"42","author":"Endele S.","year":"2010","unstructured":"Endele S.; Rosenberger G.; Geider K.; Popp B.; Tamer C.; Stefanova I.; Milh M.; Kort\u00fcm F.; Fritsch A.; Pientka F.K.; Hellenbroich Y.; Kalscheuer V.M.; Kohlhase J.; Moog U.; Rappold G.; Rauch A.; Ropers H.H.; von Spiczak S.; T\u00f6nnies H.; Villeneuve N.; Villard L.; Zabel B.; Zenker M.; Laube B.; Reis A.; Wieczorek D.; Van Maldergem L.; Kutsche K.; Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes. Nat Genet 2010,42(11),1021-1026","journal-title":"Nat Genet"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/ng.2727","volume":"45","author":"Carvill G.L.","year":"2013","unstructured":"Carvill G.L.; Regan B.M.; Yendle S.C.; O\u2019Roak B.J.; Lozovaya N.; Bruneau N.; Burnashev N.; Khan A.; Cook J.; Geraghty E.; Sadleir L.G.; Turner S.J.; Tsai M.H.; Webster R.; Ouvrier R.; Damiano J.A.; Berkovic S.F.; Shendure J.; Hildebrand M.S.; Szepetowski P.; Scheffer I.E.; Mefford H.C.; GRIN2A mutations cause epilepsy-aphasia spectrum disorders. Nat Genet 2013,45(9),1073-1076","journal-title":"Nat Genet"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ng.2726","volume":"45","author":"Lesca G.","year":"2013","unstructured":"Lesca G.; Rudolf G.; Bruneau N.; Lozovaya N.; Labalme A.; Boutry-Kryza N.; Salmi M.; Tsintsadze T.; Addis L.; Motte J.; Wright S.; Tsintsadze V.; Michel A.; Doummar D.; Lascelles K.; Strug L.; Waters P.; de Bellescize J.; Vrielynck P.; de Saint Martin A.; Ville D.; Ryvlin P.; Arzimanoglou A.; Hirsch E.; Vincent A.; Pal D.; Burnashev N.; Sanlaville D.; Szepetowski P.; GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. Nat Genet 2013,45(9),1061-1066","journal-title":"Nat Genet"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.ajhg.2016.07.013","volume":"99","author":"Li D.","year":"2016","unstructured":"Li D.; Yuan H.; Ortiz-Gonzalez X.R.; Marsh E.D.; Tian L.; McCormick E.M.; Kosobucki G.J.; Chen W.; Schulien A.J.; Chiavacci R.; Tankovic A.; Naase C.; Brueckner F.; von St\u00fclpnagel-Steinbeis C.; Hu C.; Kusumoto H.; Hedrich U.B.; Elsen G.; H\u00f6rtnagel K.; Aizenman E.; Lemke J.R.; Hakonarson H.; Traynelis S.F.; Falk M.J.; GRIN2D recurrent de novo dominant mutation causes a severe epileptic encephalopathy treatable with NMDA receptor channel blockers. Am J Hum Genet 2016,99(4),802-816","journal-title":"Am J Hum Genet"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/ng.3239","volume":"47","author":"Syrbe S.","year":"2015","unstructured":"Syrbe S.; Hedrich U.B.S.; Riesch E.; Dj\u00e9mi\u00e9 T.; M\u00fcller S.; M\u00f8ller R.S.; Maher B.; Hernandez-Hernandez L.; Synofzik M.; Caglayan H.S.; Arslan M.; Serratosa J.M.; Nothnagel M.; May P.; Krause R.; L\u00f6ffler H.; Detert K.; Dorn T.; Vogt H.; Kr\u00e4mer G.; Sch\u00f6ls L.; Mullis P.E.; Linnankivi T.; Lehesjoki A.E.; Sterbova K.; Craiu D.C.; Hoffman-Zacharska D.; Korff C.M.; Weber Y.G.; Steinlin M.; Gallati S.; Bertsche A.; Bernhard M.K.; Merkenschlager A.; Kiess W.; Gonzalez M.; Z\u00fcchner S.; Palotie A.; Suls A.; De Jonghe P.; Helbig I.; Biskup S.; Wolff M.; Maljevic S.; Sch\u00fcle R.; Sisodiya S.M.; Weckhuysen S.; Lerche H.; Lemke J.R.; De novo loss- or gain-of-function mutations in KCNA2 cause epileptic encephalopathy. Nat Genet 2015,47(4),393-399","journal-title":"Nat Genet"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1212\/WNL.0000000000003309","volume":"87","author":"Corbett M.A.","year":"2016","unstructured":"Corbett M.A.; Bellows S.T.; Li M.; Carroll R.; Micallef S.; Carvill G.L.; Myers C.T.; Howell K.B.; Maljevic S.; Lerche H.; Gazina E.V.; Mefford H.C.; Bahlo M.; Berkovic S.F.; Petrou S.; Scheffer I.E.; Gecz J.; Dominant KCNA2 mutation causes episodic ataxia and pharmacoresponsive epilepsy. Neurology 2016,87(19),1975-1984","journal-title":"Neurology"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/cge.12784","volume":"91","author":"Allou L.","year":"2017","unstructured":"Allou L.; Julia S.; Amsallem D.; El Chehadeh S.; Lambert L.; Thevenon J.; Duffourd Y.; Saunier A.; Bouquet P.; Pere S.; Mousta\u00efne A.; Ruaud L.; Roth V.; Jonveaux P.; Philippe C.; Rett-like phenotypes: expanding the genetic heterogeneity to the KCNA2 gene and first familial case of CDKL5-related disease. Clin Genet 2017,91(3),431-440","journal-title":"Clin Genet"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.ajhg.2016.03.011","volume":"98","author":"Petrovski S.","year":"2016","unstructured":"Petrovski S.; K\u00fcry S.; Myers C.T.; Anyane-Yeboa K.; Cogn\u00e9 B.; Bialer M.; Xia F.; Hemati P.; Riviello J.; Mehaffey M.; Besnard T.; Becraft E.; Wadley A.; Politi A.R.; Colombo S.; Zhu X.; Ren Z.; Andrews I.; Dudding-Byth T.; Schneider A.L.; Wallace G.; Rosen A.B.I.; Schelley S.; Enns G.M.; Corre P.; Dalton J.; Mercier S.; Latypova X.; Schmitt S.; Guzman E.; Moore C.; Bier L.; Heinzen E.L.; Karachunski P.; Shur N.; Grebe T.; Basinger A.; Nguyen J.M.; B\u00e9zieau S.; Wierenga K.; Bernstein J.A.; Scheffer I.E.; Rosenfeld J.A.; Mefford H.C.; Isidor B.; Goldstein D.B.; Germline De Novo mutations in gnb1 cause severe neurodevelopmental disability, hypotonia, and seizures. Am J Hum Genet 2016,98(5),1001-1010","journal-title":"Am J Hum Genet"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/ana.24502","volume":"79","author":"Sim J.C.","year":"2016","unstructured":"Sim J.C.; Scerri T.; Fanjul-Fern\u00e1ndez M.; Familial cortical dysplasia caused by mutation in the mTOR regulator NPRL3. Ann Neurol 2016,79(1),132-137","journal-title":"Ann Neurol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/ng.3676","volume":"48","author":"Broix L.","year":"2016","unstructured":"Broix L.; Jagline H.; Ivanova E.; Schmucker S.; Drouot N.; Clayton-Smith J.; Pagnamenta A.T.; Metcalfe K.A.; Isidor B.; Louvier U.W.; Poduri A.; Taylor J.C.; Tilly P.; Poirier K.; Saillour Y.; Lebrun N.; Stemmelen T.; Rudolf G.; Muraca G.; Saintpierre B.; Elmorjani A.; Mo\u00efse M.; Weirauch N.B.; Guerrini R.; Boland A.; Olaso R.; Masson C.; Tripathy R.; Keays D.; Beldjord C.; Nguyen L.; Godin J.; Kini U.; Nischk\u00e9 P.; Deleuze J.F.; Bahi-Buisson N.; Sumara I.; Hinckelmann M.V.; Chelly J.; Mutations in the HECT domain of NEDD4L lead to AKT-mTOR pathway deregulation and cause periventricular nodular heterotopia. Nat Genet 2016,48(11),1349-1358","journal-title":"Nat Genet"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nm.3824","volume":"21","author":"Lim J.S.","year":"2015","unstructured":"Lim J.S.; Kim W.I.; Kang H-C.; Kim S.H.; Park A.H.; Park E.K.; Cho Y.W.; Kim S.; Kim H.M.; Kim J.A.; Kim J.; Rhee H.; Kang S.G.; Kim H.D.; Kim D.; Kim D.S.; Lee J.H.; Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy. Nat Med 2015,21(4),395-400","journal-title":"Nat Med"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1212\/WNL.0000000000001305","volume":"84","author":"Thomas R.H.","year":"2015","unstructured":"Thomas R.H.; Zhang L.M.; Carvill G.L.; Archer J.S.; Heavin S.B.; Mandelstam S.A.; Craiu D.; Berkovic S.F.; Gill D.S.; Mefford H.C.; Scheffer I.E.; CHD2 myoclonic encephalopathy is frequently associated with self-induced seizures. Neurology 2015,84(9),951-958","journal-title":"Neurology"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.ejmg.2015.09.007","volume":"58","author":"Goldstein J.H.R.","year":"2015","unstructured":"Goldstein J.H.R.; Tim-Aroon T.; Shieh J.; Merrill M.; Deeb K.K.; Zhang S.; Bass N.E.; Bedoyan J.K.; Novel SMC1A frameshift mutations in children with developmental delay and epilepsy. Eur J Med Genet 2015,58(10),562-568","journal-title":"Eur J Med Genet"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1074\/jbc.M114.609156","volume":"290","author":"Liu J.C.","year":"2015","unstructured":"Liu J.C.; Ferreira C.G.; Yusufzai T.; Human CHD2 is a chromatin assembly ATPase regulated by its chromo- and DNA-binding domains. J Biol Chem 2015,290(1),25-34","journal-title":"J Biol Chem"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ejmg.2015.10.005","volume":"58","author":"Fjaer R.","year":"2015","unstructured":"Fjaer R.; Brodtkorb E.; \u00d8ye A.M.; Sheng Y.; Vigeland M.D.; Kvistad K.A.; Backe P.H.; Selmer K.K.; Generalized epilepsy in a family with basal ganglia calcifications and mutations in SLC20A2 and CHRNB2. Eur J Med Genet 2015,58(11),624-628","journal-title":"Eur J Med Genet"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.ejmg.2016.05.017","volume":"59","author":"Rocha H.","year":"2016","unstructured":"Rocha H.; Sampaio M.; Rocha R.; Fernandes S.; Le\u00e3o M.; MEF2C haploinsufficiency syndrome: Report of a new MEF2C mutation and review. Eur J Med Genet 2016,59(9),478-482","journal-title":"Eur J Med Genet"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1212\/WNL.0000000000001211","volume":"84","author":"Larsen J.","year":"2015","unstructured":"Larsen J.; Carvill G.L.; Gardella E.; Kluger G.; Schmiedel G.; Barisic N.; Depienne C.; Brilstra E.; Mang Y.; Nielsen J.E.; Kirkpatrick M.; Goudie D.; Goldman R.; J\u00e4hn J.A.; Jepsen B.; Gill D.; D\u00f6cker M.; Biskup S.; McMahon J.M.; Koeleman B.; Harris M.; Braun K.; de Kovel C.G.; Marini C.; Specchio N.; Dj\u00e9mi\u00e9 T.; Weckhuysen S.; Tommerup N.; Troncoso M.; Troncoso L.; Bevot A.; Wolff M.; Hjalgrim H.; Guerrini R.; Scheffer I.E.; Mefford H.C.; M\u00f8ller R.S.; The phenotypic spectrum of SCN8A encephalopathy. Neurology 2015,84(5),480-489","journal-title":"Neurology"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S1474-4422(15)00199-4","volume":"14","author":"Consortium E.","year":"2015","unstructured":"Consortium E.; A roadmap for precision medicine in the epilepsies. Lancet Neurol 2015,14(12),1219-1228","journal-title":"Lancet Neurol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ana.24229","volume":"76","author":"Bearden D.","year":"2014","unstructured":"Bearden D.; Strong A.; Ehnot J.; DiGiovine M.; Dlugos D.; Goldberg E.M.; Targeted treatment of migrating partial seizures of infancy with quinidine. Ann Neurol 2014,76(3),457-461","journal-title":"Ann Neurol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s13311-015-0372-8","volume":"13","author":"Boerma R.S.","year":"2016","unstructured":"Boerma R.S.; Braun K.P.; van den Broek M.P.; van Berkestijn F.M.; Swinkels M.E.; Hagebeuk E.O.; Lindhout D.; van Kempen M.; Boon M.; Nicolai J.; de Kovel C.G.; Brilstra E.H.; Koeleman B.P.; Remarkable phenytoin sensitivity in 4 children with SCN8A-related epilepsy: A molecular neuropharmacological approach. Neurotherapeutics 2016,13(1),192-197","journal-title":"Neurotherapeutics"},{"key":"ref=60","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000096","volume":"2","author":"Millichap J.J.","year":"2016","unstructured":"Millichap J.J.; Park K.L.; Tsuchida T.; Ben-Zeev B.; Carmant L.; Flamini R.; Joshi N.; Levisohn P.M.; Marsh E.; Nangia S.; Narayanan V.; Ortiz-Gonzalez X.R.; Patterson M.C.; Pearl P.L.; Porter B.; Ramsey K.; McGinnis E.L.; Taglialatela M.; Tracy M.; Tran B.; Venkatesan C.; Weckhuysen S.; Cooper E.C.; KCNQ2 encephalopathy: Features, mutational hot spots, and ezogabine treatment of 11 patients. Neurol Genet 2016,2(5)","journal-title":"Neurol Genet"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nn.4205","volume":"19","author":"Johnson M.R.","year":"2016","unstructured":"Johnson M.R.; Shkura K.; Langley S.R.; Delahaye-Duriez A.; Srivastava P.; Hill W.D.; Rackham O.J.; Davies G.; Harris S.E.; Moreno-Moral A.; Rotival M.; Speed D.; Petrovski S.; Katz A.; Hayward C.; Porteous D.J.; Smith B.H.; Padmanabhan S.; Hocking L.J.; Starr J.M.; Liewald D.C.; Visconti A.; Falchi M.; Bottolo L.; Rossetti T.; Danis B.; Mazzuferi M.; Foerch P.; Grote A.; Helmstaedter C.; Becker A.J.; Kaminski R.M.; Deary I.J.; Petretto E.; Systems genetics identifies a convergent gene network for cognition and neurodevelopmental disease. Nat Neurosci 2016,19(2),223-232","journal-title":"Nat Neurosci"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"6031","DOI":"10.1038\/ncomms7031","volume":"6","author":"Johnson M.R.","year":"2015","unstructured":"Johnson M.R.; Behmoaras J.; Bottolo L.; Krishnan M.L.; Pernhorst K.; Santoscoy P.L.M.; Rossetti T.; Speed D.; Srivastava P.K.; Chadeau-Hyam M.; Hajji N.; Dabrowska A.; Rotival M.; Razzaghi B.; Kovac S.; Wanisch K.; Grillo F.W.; Slaviero A.; Langley S.R.; Shkura K.; Roncon P.; De T.; Mattheisen M.; Niehusmann P.; O\u2019Brien T.J.; Petrovski S.; von Lehe M.; Hoffmann P.; Eriksson J.; Coffey A.J.; Cichon S.; Walker M.; Simonato M.; Danis B.; Mazzuferi M.; Foerch P.; Schoch S.; De Paola V.; Kaminski R.M.; Cunliffe V.T.; Becker A.J.; Petretto E.; Systems genetics identifies Sestrin 3 as a regulator of a proconvulsant gene network in human epileptic hippocampus. Nat Commun 2015,6,6031","journal-title":"Nat Commun"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/cge.13414","volume":"95","author":"Myers K.A.","year":"2019","unstructured":"Myers K.A.; Johnstone D.L.; Dyment D.A.; Epilepsy genetics: Current knowledge, applications, and future directions. Clin Genet 2019,95(1),95-111","journal-title":"Clin Genet"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1242\/dmm.002139","volume":"3","author":"Hortopan G.A.","year":"2010","unstructured":"Hortopan G.A.; Dinday M.T.; Baraban S.C.; Zebrafish as a model for studying genetic aspects of epilepsy. Dis Model Mech 2010,3(3-4),144-148","journal-title":"Dis Model Mech"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1038\/ncomms3410","volume":"4","author":"Baraban S.C.","year":"2013","unstructured":"Baraban S.C.; Dinday M.T.; Hortopan G.A.; Drug screening in SCN1A zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment. Nat Commun 2013,4,2410","journal-title":"Nat Commun"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/brain\/aww342","volume":"140","author":"Griffin A.","year":"2017","unstructured":"Griffin A.; Hamling K.R.; Knupp K.; Hong S.; Lee L.P.; Baraban S.C.; Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome. Brain 2017,140(3),669-683","journal-title":"Brain"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/1535759718822846","volume":"19","author":"Ingusci S.","year":"2019","unstructured":"Ingusci S.; Cattaneo S.; Verlengia G.; Zucchini S.; Simonato M.; A matter of genes: The hurdles of gene therapy for epilepsy. Epilepsy Curr 2019,19(1),38-43","journal-title":"Epilepsy Curr"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13073-015-0214-7","volume":"7","author":"Myers C.T.","year":"2015","unstructured":"Myers C.T.; Mefford H.C.; Advancing epilepsy genetics in the genomic era. Genome Med 2015,7,91-99","journal-title":"Genome Med"}],"container-title":["Current Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/178907","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T04:21:01Z","timestamp":1589862061000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/178907\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,25]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,4,25]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1566523220666200131142423","relation":{},"ISSN":["1566-5232"],"issn-type":[{"value":"1566-5232","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,25]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-10-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}